Clariane SE (CLARI) - Net Assets
Based on the latest financial reports, Clariane SE (CLARI) has net assets worth €3.92 Billion EUR (≈ $4.58 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.36 Billion ≈ $16.79 Billion USD) and total liabilities (€10.44 Billion ≈ $12.21 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Clariane SE strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.92 Billion |
| % of Total Assets | 27.27% |
| Annual Growth Rate | 16.45% |
| 5-Year Change | 4.09% |
| 10-Year Change | 92.37% |
| Growth Volatility | 44.72 |
Clariane SE - Net Assets Trend (2004–2025)
This chart illustrates how Clariane SE's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Clariane SE stock valuation.
Annual Net Assets for Clariane SE (2004–2025)
The table below shows the annual net assets of Clariane SE from 2004 to 2025. Also explore Clariane SE annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €3.92 Billion ≈ $4.58 Billion |
-2.55% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
+2.12% |
| 2023-12-31 | €3.94 Billion ≈ $4.60 Billion |
+1.80% |
| 2022-12-31 | €3.87 Billion ≈ $4.52 Billion |
+2.75% |
| 2021-12-31 | €3.76 Billion ≈ $4.40 Billion |
+13.30% |
| 2020-12-31 | €3.32 Billion ≈ $3.88 Billion |
+29.30% |
| 2019-12-31 | €2.57 Billion ≈ $3.00 Billion |
+0.06% |
| 2018-12-31 | €2.57 Billion ≈ $3.00 Billion |
+3.77% |
| 2017-12-31 | €2.47 Billion ≈ $2.89 Billion |
+21.49% |
| 2016-12-31 | €2.04 Billion ≈ $2.38 Billion |
+5.33% |
| 2015-12-31 | €1.93 Billion ≈ $2.26 Billion |
+1.65% |
| 2014-12-31 | €1.90 Billion ≈ $2.22 Billion |
+147.59% |
| 2013-12-31 | €768.43 Million ≈ $898.37 Million |
+4.87% |
| 2012-12-31 | €732.75 Million ≈ $856.66 Million |
+1.38% |
| 2011-12-31 | €722.78 Million ≈ $845.00 Million |
+0.62% |
| 2010-12-31 | €718.32 Million ≈ $839.79 Million |
+2.51% |
| 2009-12-31 | €700.70 Million ≈ $819.19 Million |
+8.63% |
| 2008-12-31 | €645.02 Million ≈ $754.09 Million |
-0.40% |
| 2007-12-31 | €647.61 Million ≈ $757.13 Million |
+2.79% |
| 2006-12-31 | €630.04 Million ≈ $736.59 Million |
+50.69% |
| 2005-12-31 | €418.09 Million ≈ $488.79 Million |
+161.20% |
| 2004-12-31 | €160.06 Million ≈ $187.13 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Clariane SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 145370200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.45 Billion | 40.23% |
| Common Stock | €3.57 Million | 0.10% |
| Other Comprehensive Income | €641.90 Million | 17.76% |
| Other Components | €1.51 Billion | 41.91% |
| Total Equity | €3.61 Billion | 100.00% |
Clariane SE Competitors by Market Cap
The table below lists competitors of Clariane SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Digiwin Software Co Ltd
SHE:300378
|
$1.43 Billion |
|
Qingdao Haier Biomedical Co Ltd
SHG:688139
|
$1.43 Billion |
|
Shenzhen Kingdom SCI Tech Co Ltd
SHG:600446
|
$1.43 Billion |
|
RONESANS GAYRIMENKUL YAT.
IS:RGYAS
|
$1.43 Billion |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
$1.43 Billion |
|
ShanXi Coking Co Ltd
SHG:600740
|
$1.42 Billion |
|
Kyland Technology Co Ltd
SHE:300353
|
$1.42 Billion |
|
Sarawak Oil Palms Bhd
KLSE:5126
|
$1.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clariane SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,692,284,000 to 3,613,664,000, a change of -78,620,000 (-2.1%).
- Net income of 1,600,000 contributed positively to equity growth.
- Dividend payments of 69,956,000 reduced retained earnings.
- Share repurchases of 3,565,000 reduced equity.
- Other comprehensive income decreased equity by 66,506,000.
- Other factors increased equity by 63,327,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.60 Million | +0.04% |
| Dividends Paid | €69.96 Million | -1.94% |
| Share Repurchases | €3.56 Million | -0.1% |
| Other Comprehensive Income | €-66.51 Million | -1.84% |
| Other Changes | €63.33 Million | +1.75% |
| Total Change | €- | -2.13% |
Book Value vs Market Value Analysis
This analysis compares Clariane SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.39x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.74x to 0.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €5.33 | €3.93 | x |
| 2005-12-31 | €13.24 | €3.93 | x |
| 2006-12-31 | €20.90 | €3.93 | x |
| 2007-12-31 | €21.29 | €3.93 | x |
| 2008-12-31 | €19.42 | €3.93 | x |
| 2009-12-31 | €19.97 | €3.93 | x |
| 2010-12-31 | €19.92 | €3.93 | x |
| 2011-12-31 | €19.50 | €3.93 | x |
| 2012-12-31 | €19.07 | €3.93 | x |
| 2013-12-31 | €19.98 | €3.93 | x |
| 2014-12-31 | €22.15 | €3.93 | x |
| 2015-12-31 | €22.22 | €3.93 | x |
| 2016-12-31 | €22.30 | €3.93 | x |
| 2017-12-31 | €25.86 | €3.93 | x |
| 2018-12-31 | €26.54 | €3.93 | x |
| 2019-12-31 | €26.56 | €3.93 | x |
| 2020-12-31 | €29.84 | €3.93 | x |
| 2021-12-31 | €28.59 | €3.93 | x |
| 2022-12-31 | €29.38 | €3.93 | x |
| 2023-12-31 | €24.62 | €3.93 | x |
| 2024-12-31 | €15.96 | €3.93 | x |
| 2025-12-31 | €10.16 | €3.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clariane SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.03%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 3.82x
- Recent ROE (0.04%) is below the historical average (2.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 4.03% | 4.01% | 0.29x | 3.43x | €-9.53 Million |
| 2005 | 7.44% | 10.46% | 0.24x | 2.96x | €-10.16 Million |
| 2006 | 3.15% | 3.84% | 0.41x | 1.99x | €-42.94 Million |
| 2007 | 3.62% | 3.80% | 0.36x | 2.63x | €-40.69 Million |
| 2008 | 2.88% | 2.31% | 0.45x | 2.76x | €-44.68 Million |
| 2009 | 2.17% | 1.76% | 0.47x | 2.64x | €-53.94 Million |
| 2010 | 3.52% | 2.67% | 0.49x | 2.70x | €-45.47 Million |
| 2011 | 3.08% | 2.14% | 0.49x | 2.97x | €-48.61 Million |
| 2012 | 3.27% | 2.10% | 0.50x | 3.13x | €-47.95 Million |
| 2013 | 3.83% | 2.11% | 0.59x | 3.11x | €-46.01 Million |
| 2014 | 3.22% | 2.76% | 0.42x | 2.76x | €-129.15 Million |
| 2015 | 3.05% | 2.28% | 0.45x | 3.00x | €-133.58 Million |
| 2016 | 6.49% | 4.40% | 0.46x | 3.21x | €-71.01 Million |
| 2017 | 6.63% | 5.22% | 0.44x | 2.89x | €-82.92 Million |
| 2018 | 4.82% | 3.69% | 0.44x | 2.98x | €-132.49 Million |
| 2019 | 4.48% | 3.17% | 0.33x | 4.28x | €-141.14 Million |
| 2020 | 1.25% | 1.04% | 0.29x | 4.18x | €-276.30 Million |
| 2021 | 2.61% | 2.20% | 0.29x | 4.10x | €-258.21 Million |
| 2022 | 0.62% | 0.50% | 0.30x | 4.12x | €-331.86 Million |
| 2023 | -2.94% | -2.11% | 0.33x | 4.24x | €-463.62 Million |
| 2024 | -1.49% | -1.04% | 0.37x | 3.86x | €-424.35 Million |
| 2025 | 0.04% | 0.03% | 0.38x | 3.82x | €-359.77 Million |
Industry Comparison
This section compares Clariane SE's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $1,007,616,667
- Average return on equity (ROE) among peers: 28.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clariane SE (CLARI) | €3.92 Billion | 4.03% | 2.67x | $1.43 Billion |
| EMEIS SA (EMEIS) | $1.89 Billion | 71.75% | 6.36x | $2.24 Billion |
| Ramsay Generale De Sante (GDS) | $1.10 Billion | 5.92% | 5.08x | $1.18 Billion |
| LNA Sante SA (LNA) | $35.72 Million | 6.56% | 2.09x | $271.76 Million |
About Clariane SE
Clariane SE provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. It operates long-term care and short stay nursing homes. The company also provides inpatient and outpatient services, full-time hospitalization, day hospitalization, and outpatient care, and operates post-acute and rehabilitation care … Read more